IGC Pharma (FRA:IGS1) Operating Margin %: -775.91% (As of Mar. 2026)


FRA:IGS1 IGC Pharma Inc FRA:IGS1
28 GF Score
Price €0.24
GF Value €0.22
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Operating Margin %?

IGC Pharma FRA:IGS1 +2.61% 28 Operating Margin % is -775.91% as of Mar. 2026. GuruFocus rates FRA:IGS1 with a GF Score™ of 28/100 and a GF Value™ of €0.22 (Fairly Valued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, IGC Pharma ranks worse than 77.12% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. IGC Pharma's Operating Income for the three months ended in Mar. 2026 was €-2.13 Mil. IGC Pharma's Revenue for the three months ended in Mar. 2026 was €0.27 Mil. Therefore, IGC Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was -775.91%.

Warning Sign:

IGC Pharma Inc operating margin has been in a 5-year decline. The average rate of decline per year is -12.9%.

The historical rank and industry rank for IGC Pharma's Operating Margin % or its related term are showing as below:

FRA:IGS1' s Operating Margin % Range Over the Past 10 Years
Min: -3886.15   Med: -469.91   Max: -40.65
Current: -860.29


FRA:IGS1's Operating Margin % is ranked worse than
77.12% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs FRA:IGS1: -860.29

IGC Pharma's 5-Year Average Operating Margin % Growth Rate was -12.90% per year.

IGC Pharma's Operating Income for the three months ended in Mar. 2026 was €-2.13 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-8.76 Mil.


IGC Pharma  (FRA:IGS1) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


IGC Pharma Operating Margin % Related Terms


IGC Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Operating Margin % Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -971.88 -3,891.39 -1,269.92 -728.70 -585.71

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -428.20 -581.69 -1,515.34 -840.13 -775.91

FRA:IGS1 vs CRVO, NEUP, CELU: Operating Margin % Comparison

For the Biotechnology subindustry, IGC Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Operating Margin % falls into.


FRA:IGS1
28GF Score
IGC Pharma Inc FRA:IGS1
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

IGC Pharma's Operating Margin % for the fiscal year that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (A: Mar. 2025 ) / Revenue (A: Mar. 2025 )
=-6.888 / 1.176
=-585.71 %

IGC Pharma's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-2.126 / 0.274
=-775.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -775.91% mean?
IGC Pharma (FRA:IGS1) has a Operating Margin % of -775.91% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #728 out of 944 companies in the Biotechnology industry, placing it in the top 77.1%.
Is IGC Pharma's Operating Margin % too high?
IGC Pharma's current Operating Margin % is -775.91%. Based on the distribution chart, IGC Pharma ranks #728 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IGC Pharma has a GF Score™ of 28/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Operating Margin % compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #728 out of 944 companies for Operating Margin %. This places IGC Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on IGC Pharma and its competitors. IGC Pharma's current Operating Margin % is -775.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (FRA:IGS1) is currently considered Fairly Valued. The stock's GF Value™ is €0.22, compared to a current price of €0.24 — trading 7.3% above its estimated fair value. The current Operating Margin % is -775.91%. IGC Pharma's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For IGC Pharma (FRA:IGS1), the current Operating Margin % is -775.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (FRA:IGS1) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of €0.24 is trading 7.3% above its estimated GF Value™ of €0.22. GuruFocus considers IGC Pharma to be Fairly Valued.

Key valuation signals for FRA:IGS1:

  • Operating Margin %: -775.91%
  • GF Value™: €0.22 vs. price of €0.24 (7.3% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:IGS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IGC Pharma Business Description

Other Exchanges IGC:USA
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
28GF Score

Get the complete analysis for FRA:IGS1

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.22
GF Value